Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: A potential ticagrelor-angiotensin receptor blocker interaction?

Clinical Cardiology

Volumn 35, Issue 11, 2012, Pages 647-648

  Dinicolantonio, James J ^a   Serebruany, Victor L ^b  

^a Wegmans Pharmacy   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CLOPIDOGREL; CREATININE; TICAGRELOR;

ANGIONEUROTIC EDEMA; BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG SAFETY; DYSPNEA; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LOADING DRUG DOSE; MORTALITY; OUTCOME ASSESSMENT; REVIEW; RISK FACTOR; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADENOSINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DRUG INTERACTIONS; DYSPNEA; GLOMERULAR FILTRATION RATE; HEMORRHAGE; HUMANS; KIDNEY; KIDNEY DISEASES; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; TICLOPIDINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84869499419     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22063     Document Type: Review

References (3)

1. Wallentin L, Becker RC, Budaj A, et al. the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045-1057.
2. The FDA, ticagrelor review of complete response. http://www.accessdata. fda.gov/drugsatfda-docs/nda/2011/022433Orig1s000MedR.pdf. Accessed May 10, 2012.
3. The FDA, ticagrelor review of complete response. http://www.accessdata. fda.gov/drugsatfda-docs/nda/2011/022433Orig1s000TOC.cfm. Accessed May 10, 2012.